CD8A and neoplasm: In mice treated with intratumoral injection of OVA257–264 peptide, a larger number of CD8+ T-cells had infiltrated the RMA tumor 24 days after the transfer of OT-I CTLs and 10 days after the last intratumoral injection of OVA257–264 peptide.